Ocular Melanoma Foundation is categorized under Commercial Medical Research in Washington, DC and active since 2013.
Ocular Melanoma Foundation was established in 2013, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact at the company’s single location by writing to 1000 Conn Avenue Nw # 900, Washington, District of Columbia DC 20036 or by phoning (202) 257-0517. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Ocular Melanoma Foundation |
| Address: | 1000 Conn Avenue Nw # 900, Washington, District of Columbia 20036 |
| Phone Number: | (202) 257-0517 |
| Annual Revenue (USD): | $50.000 to $99.999 |
| Founded: | 2013 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Ocular Melanoma Foundation was started in 2013 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.
Feel free to contact for inquiries that concern Ocular Melanoma Foundation by calling the company number (202) 257-0517, as your correspondence is most welcome. Additionally, the physical location of the single location of Ocular Melanoma Foundation can be found at the coordinates 38.902696,-77.039659 as well as the street address 1000 Conn Avenue Nw # 900 in Washington, District of Columbia 20036.
For its online presence, you may visit Ocular Melanoma Foundation’s website at and engage with its social media outlets through on Twitter and on Facebook.